Immunization Schedule Alert Platform
NCT03705455 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 1800
Last updated 2018-10-15
Summary
The ISAP study is investigating the efficacy of SMS messages in improving routine childhood Immunization timeliness and completeness in Nigeria.
Conditions
- Immunization
Interventions
- BEHAVIORAL
-
ISAP SMS
ISAP SMS is a text message for caregivers use that provides immunization schedule and vaccine availability at the nearest immunization clinic.
Sponsors & Collaborators
-
Lifespan Healthcare Resource Limited
lead OTHER
Principal Investigators
-
Emmanuel Ihedioha, MBBS · Lifespan Healthcare Resource
Study Design
- Allocation
- RANDOMIZED
- Purpose
- PREVENTION
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 6 Weeks
- Max Age
- 12 Months
- Sex
- ALL
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2018-11-01
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- Nigeria
Study Locations
More Related Trials
-
Text Message Vaccine Reminders for Adolescents With Chronic Medical Conditions
NCT02231957 ·Status: COMPLETED ·Phase: NA
-
Safety and Immunogenicity of Tdap Vaccine Compared to DTaP Vaccine in Children 4 to 6 Years of Age
NCT00467519 ·Status: COMPLETED ·Phase: PHASE3
-
A School Health Center Intervention to Increase Adolescent Vaccination
NCT01595542 ·Status: COMPLETED ·Phase: NA
-
Parental Views Related to Colorado State Legislation About Vaccinations, Schools, and Child Care Centers
NCT02957344 ·Status: COMPLETED
-
Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™
NCT00802867 ·Status: COMPLETED ·Phase: PHASE4
-
Phone Text Message Reminders on Compliance With Human Rabies Post Exposure Prophylaxis Project
NCT05350735 ·Status: COMPLETED ·Phase: NA
-
Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine
NCT00662870 ·Status: COMPLETED ·Phase: PHASE3
-
Maternal Tdap Immunization in Guatemala
NCT02301702 ·Status: COMPLETED ·Phase: PHASE2
-
Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines
NCT00254917 ·Status: COMPLETED ·Phase: PHASE4
-
Effectiveness of Adacel Vaccination in Pregnancy at Preventing Pertussis in Infants < 2 Months of Age in the United States
NCT05040802 ·Status: COMPLETED
-
Study of the Tdap Combined Vaccine (ADACEL™) as a Booster Dose in Healthy Adults and Children in China
NCT01933776 ·Status: COMPLETED ·Phase: PHASE1
-
COVID-19 Booster Dose Reminder/Recall for Adolescents
NCT05571657 ·Status: UNKNOWN ·Phase: NA
-
Pertussis Vaccine in Healthy Pregnant Women
NCT00707148 ·Status: COMPLETED ·Phase: PHASE1
-
Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age
NCT01346293 ·Status: COMPLETED ·Phase: PHASE3
-
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination in Study NCT01267058
NCT00548171 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Immunogenicity of DAPTACEL® as 5th Dose in Children 4 to 6 Years Old After 4 Doses of Pentacel™ or DAPTACEL®
NCT00258895 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Menactra® in Children Aged 4 to 6 Years When Administered Concomitantly With a Fifth Dose of DAPTACEL®
NCT00355121 ·Status: COMPLETED ·Phase: PHASE2
-
Immunogenicity & Reactogenicity of Boostrix 10 Years After Previous Booster Vaccination.
NCT00610168 ·Status: COMPLETED ·Phase: PHASE4
-
Pertussis Maternal Immunization Study
NCT00553228 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Dengue Effectiveness Study in the Philippines
NCT03803618 ·Status: COMPLETED
-
Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients
NCT00715234 ·Status: COMPLETED ·Phase: NA
-
Understanding Typhoid Disease After Vaccination
NCT01405521 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Assess Safety & Immunogenicity of GSK Biologicals' Boostrix (dTpa) Vaccine vs. Chinese DT Vaccine
NCT00452686 ·Status: COMPLETED ·Phase: PHASE3
-
Safety and Dose Ranging Study of Acellular Pertussis and Acellular Pertussis -Tetanus-Diphtheria Booster Vaccines in Healthy Adults Ages 18 to 40 Years
NCT01529645 ·Status: COMPLETED ·Phase: PHASE1
-
Persistence Study of GSK Biologicals' Tdap Vaccine 1, 3, 5 and 9 Years Following Administration as an Initial Single Dose in Healthy Young Adults and to Evaluate the Immunogenicity and Safety of Boostrix as a Second Dose of Tdap, When Administered at Year 9
NCT00489970 ·Status: COMPLETED ·Phase: PHASE3